The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest Statements Conflict of interest Within the last 36 months, FK has served on scientific advisory panels and/or been part of speaker's bureaus for, served as a consultant to and/or received research support from Amgen, AstraZeneca, Boehringer Ingelheim, Eli Lilly, Gubra, MedImmune, MSD/Merck, Mundipharma, Norgine, Novo Nordisk, Sanofi and Zealand Pharma
Therefore, when you take carnitine is probably not as important as just remembering to take it
mTORC1 and p53
A person at 170 pounds with 25% body fat has a fundamentally different health profile than a person at 170 pounds with 35% body fat
One-two-punch therapies with RSL3 improve the survival of a mouse model of ovarian cancer To investigate the therapeutic potential of RSL3 as a senolytic in an immunocompetent setting, we used the previously described ID8 Trp53 / ovarian cancer model 57
No formal human interaction study exists
